Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q1 2025 Earnings Presentation
32 slides from Neuland Laboratories's earnings presentation, 2024
Slide 1: Neuland Laboratories Limited Investor Presentation Q1FY25
Neuland Laboratories Limited Investor Presentation Q1FY25
Slide 2: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 3: Table of Content
Table of Content Q1FY25 Company Business Our Shareholder Annexure Highlights Overview Strategy Businesses Information 3
Slide 4: Q1FY25 Highlights
Q1FY25 Highlights 4
Slide 5: Management Commentary
Management Commentary SUCHETH DAVULURI “We recorded our highest ever quarterly revenues in Q1FY25 led by growth in the CMS business even as we recorded healthy EBITDA margins. We continue to maintain that FY25 will be a year of normalisation of revenue growth and subsequently margins as we continue
Slide 6: Q1FY25 Business and Financial Highlights
Business and Financial Highlights Q1FY25 Business and Financial Highlights CMS CMS revenues driven by growth from commercial molecules and molecules close to commercialization. GDS Specialty business driven by Dorzolamide and Donepezil In Prime segment Mirtazapine, Levetiracetam and Escitalopram wer
Slide 7: Q1FY25 Financial Highlights
Q1FY25 Financial Highlights Total Income EBITDA PAT* EPS 22.1% (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 33.4% 31.1% 28.7% 21.2% 20.4% 28.9% 27.2% 17.3% 17.0% 89.1 69.4 140.3 444.4 98.3 420.8 394.9 390.4 365.0 76.6 128.6 80.7 122.7 112.2 62.9 67.6 62.2 99.3 52.7 48.5 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q1FY24
Slide 8: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio(x) ROCE (%) Fixed Asset Turnover (x) Debt to Equity (x) 3.5 32.8% 3.1 30.9% 2.7 2.1 2.1 0.3 2.4 21.3% 1.7 2.1 1.6 0.2 1.5 13.5% 9.7% 0.1 0.1 0.1 FY21 FY22 FY23 FY24 Q1FY25 FY21 FY22 FY23 FY24 Q1FY25 FY21 FY22 FY23 FY24 Q1FY25 FY21 FY22 FY23 FY24 Q1FY25 Particu
Slide 9: Key Operating Metrics Q1FY25
Key Operating Metrics Q1FY25 Segment Revenue Prime Specialty Top 10 & Top 5 Products Top 10 Top 10 & Top 5 Customers Top 10 CMS Others Top 5 Top 5 5% 3% 6% 6% 98% 98% 98% 7% 96% 91% 93% 44% 74% 71% 70% 55% 49% 46% 53% 72% 64% 63% 57% 60% 47% 44% 25% 20% 24% 14% 21% 26% 21% 25% 23% 27% Q1FY24 Q2FY24
Slide 10: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr YoY Movement No. of active CMS projects Q1FY25 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg* Commercial Total 170 API 8 8 12 3 8 8 47 104 Intermediate 9 4 11 4 6 10 44 65 Grand Total 17 12 23 7 14 18 91 55 Q1FY24 Q1FY25 Q1FY24 Pre-Clinical P-1 P-2 P-3 P
Slide 11: Company Overview
Company Overview 11
Slide 12: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 941,000 Liters Facilities Inspected by Supported 3 ND
Slide 13: Key Facts
Key Facts 40+ 978+ 100+ 78% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 69 941KL 1695 Countries Served Active US DMFs API Manufacturing Employees Capacity 13
Slide 14: Board Of Directors
Board Of Directors Dr. Davuluri D. Sucheth Rao D. Saharsh Rao Dr. Christopher M. Ms. Pallavi Joshi Rama Mohan Rao Vice Chairman & Vice Chairman & Cimarusti Bhakru Executive Chairman Chief Executive Managing Director Non-executive Independent Officer Director Director Ms. Nirmala Murthy Mr. Homi Rust
Slide 15: Key Milestones
Key Milestones Our Journey 2018 2019 2020 2021 2023 2024 Acquisition of Increased flow of projects 100 M+ revenue over Unit – III Crossed INR 10 bn US FDA audit advanced from CMS Japan. 75 live CMS projects Commercialization revenue. of Unit-I intermediates & Active emphasis on supply US FDA audit o
Slide 16: Our Global Presence
Our Global Presence EUROPE BD office in Lugano, 48% Switzerland Since 2021 APAC NORTH AMERICA BD office in 2% 42% Princeton, New Jersey Since 2004 JAPAN BD office in 3% Tokyo, Japan Since 2007 LATAM INDIA 2% Headquarters in MENA 1% Hyderabad, India 3 Manufacturing Units Manufacturing and Development
Slide 17: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 239 kL Pashamylaram, Hyderabad 381 kL Gaddapotharam, Hyderabad 321 kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 7 & 8 Hy
Slide 18: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs with space • Several NCE APIs added in NDA or for expansion commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • Dedica
Slide 19: Regulatory Filings
Regulatory Filings 69 32 10 17 20 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 274 ~499 29 978+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Polan
Slide 20: Financial Highlights FY2015-2024
Financial Highlights FY2015-2024 Rs. Cr FY2015 FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 Total Income 469.9 511.6 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 EBITDA 67.4 81.5 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 EBITDA Margin 14.3% 15.9% 18.1% 10.2% 9.2% 13.7% 1
Slide 21: Business Strategy
Business Strategy 21
Slide 22: Neuland Strategy Framework
Neuland Strategy Framework Strategic Priority - IV Strategic Priority - I Digitize planning to delivery processes, financial processes, Build deep competency in complementary new customer servicing processes and build company-wide technologies like bio-catalysis, flow chemistry, and dashboard provid
Slide 23: Our Businesses
Our Businesses 23
Slide 24: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Process Investigation Department (PID) • Non-competitive advantage (does not majorly
Slide 25: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 26: Shareholder Information
Shareholder Information 26
Slide 27: Shareholding Details
Shareholding Details Share Information (as on 30th June 2024) NSE Ticker NEULANDLAB BSE Ticker 524558 Others 35% Market Cap (Rs. Cr) 9,601 Promoters 33% % free-float 67.28% Free-float market cap (Rs. Cr) 6,459 Shares Outstanding 1,28,29,889 DII 3M Average Daily Traded Volume (ADTV) 42,902 FII 6% (Sh
Slide 28: Annexure
Annexure 28
Slide 29: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Particulars (Rs Cr) Q1FY25 Q1FY24 YoY (%) Q4FY24 QoQ (%) Total Income 444.4 365.0 21.7% 390.4 13.8% EBITDA 128.6 99.3 29.5% 112.2 14.7% EBITDA Margin 28.9% 27.2% 174 bps 28.7% 21 bps Exceptional Item 20.6* - - - - Profit Before Tax* 130.3 83.5 56.1% 92.1 41.5% PBT
Slide 30: Sustainability Framework
Sustainability Framework Our Key Goals (included in our Executives’ and Focus Our Priorities Our Commitments Goal Area Leaders’ Balanced Scorecard) • Effluent and Waste3’4 • Reduction in direct emissions Direct emissions • FY35: Carbon neutrality: 30%* reduction • Water3’4 • Efforts to water neutral
Slide 31: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 32: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: mir@Neulandlabs.com Ravi Udeshi / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com